FDA grants fast track designation for glioblastoma treatment

The U.S. Food and Drug Administration has granted fast track designation for GLR2007 (Gan & Lee Pharmaceuticals Co, Ltd) for the treatment of patients with glioblastoma, according to a press release.

GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor.

The 1-year, 2-year, and 5 years survival rates for glioblastoma are 39.3%, 16.9%, and 5.5%, respectively, with untreated patients only surviving on average 3 months.

“The poor prognosis and low survival rates for glioblastomas, demonstrate an unmet need for new treatment options,” said Julius Huang, Director of Global Clinical Sciences, Gan & Lee.

Read the full press release here.